Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.

Armed with highly satisfactory Phase III cholesterol-lowering data, the private group is heading to market alone – though it is open to offers. 

Public Company Edition: Sage will reveal cost reductions later in the third quarter after the US FDA approved zuranolone for the smaller of two depression indications. Also, Karyopharm revealed a 20% workforce reduction, Harmony accessed up to $185m in debt and Astellas invested $50m in Poseida.

McKinsey & Company's senior partner Vikas Bhadoria, in this first instalment of a wide-ranging two-part interview with Scrip, outlines a number of use cases to define where pharma currently is and the potential value that can be unlocked as industry adopts new technologies such as generative AI, digital twins and the metaverse.